# Intraperitoneal Chemotherapy Alone or in Combination With Bevacizumab for Ovarian Cancer With Peritoneal Adhesion

> **NCT03095001** · PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 70 (estimated)

## Conditions studied

- Peritoneal Adhesion

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Carboplatin
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT03095001
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-06-01
- **Primary completion:** 2020-06-01
- **Final completion:** 2020-06-01
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2017-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03095001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03095001, "Intraperitoneal Chemotherapy Alone or in Combination With Bevacizumab for Ovarian Cancer With Peritoneal Adhesion". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03095001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*